(*4*)The health-care sector can have done poorly within the last couple of years, but analysts are bullish on it straight away . “Just two weeks into 2024, the healthcare sector has shrugged off the title of being a notable laggard in 2023,” Citi said in a recent note. Higher rates of interest were a key headwind, it noted. But Citi now expects the environment to enhance. “We expect healthcare investors can climb this wall of worry in 2024. We expect the Federal Reserve to ease its restrictive monetary policies over time. And we’re already seeing a stabilization in biotech funding.” “For those dialed into the dual unstoppable trends of longevity and innovation, nevertheless, the 2023 downturn has created opportunities. Most of the issues that held back Healthcare stocks are transitory, in our opinion, thus creating a positive setup for the sector’s potential outperformance in 2024,” the bank added. Analysts have cited biotech specifically as considered one of a couple of areas to look at . Growth stocks such those in tech and biotech often profit from rate cuts. To search for biotech stocks that did well last yr and that analysts are still positive on, CNBC Pro screened the iShares Biotechnology ETF and the SPDR S & P Biotech ETF. These were the factors used: Up more than 20% in 2023. Potential upside to average price goal of more than 40%. Buy rating of more than 70%. Seven or more analysts cover the stock. These 10 stocks were amongst those who showed up within the screen. 4 stocks stood out for being given on average more than 100% potential upside: Humacyte , Marinus Pharmaceuticals , Olema Pharmaceuticals and Ovid Therapeutics . A fifth stock — Biomea Fusion — got more than 200% upside to the typical price goal and a 75% buy rating from analysts. Biomea first got here under the highlight when Citi gave it more than 800% upside in a note last November , because the bank cited its treatment therapies having “potential benefits” over others. One other three stocks within the screen drew 100% buy rankings from analysts: Ardelyx , Cabaletta Bio and Rocket Pharmaceuticals . Of these three, Rocket Pharmaceuticals got the very best potential upside of 81.4%.